Buprenorphine for Chronic Pain

“Isn’t that the addiction drug?”

If your physician has mentioned buprenorphine and your first thought was that is the drug they give people with addiction, you are not wrong – and you are not being accused of anything. Buprenorphine is one of the three FDA-approved medications for opioid use disorder, and it has saved a great many lives in that role. But the same molecule has been an approved pain medication in the United States for more than four decades, in its own products with its own labels. A physician who brings it up is usually thinking about your breathing and your long-term safety – not about a diagnosis you do not have.

That double life is why the stigma sticks. For years, a federal “X-waiver” was required to prescribe buprenorphine for addiction, which marked it in many minds as a drug for a separate kind of patient. Congress eliminated that waiver at the end of 2022, and the DEA now treats a buprenorphine prescription like any other controlled-substance prescription. The medicine did not change. The paperwork around it did.

What buprenorphine is

Buprenorphine is an opioid, and it is honest to say so. It works at the same mu-opioid receptor that morphine, oxycodone, and fentanyl work at, and it binds there very tightly. The difference is in what it does once attached. Those other drugs are full agonists: they switch the receptor fully on, and more drug means more effect, with no natural stopping point. Buprenorphine is a partial agonist: it switches the receptor on only part of the way. For some of the receptor’s jobs, that partial signal is enough. For others, it is not.

The job that matters most for safety is breathing. In controlled studies in healthy volunteers, Dahan and colleagues found that buprenorphine’s effect on breathing reaches a ceiling – past a certain point, more drug did not suppress breathing further – while its pain-relieving effect did not show the same plateau. Fentanyl, tested the same way, kept suppressing breathing as the amount rose. This is the single property that makes buprenorphine different from the opioids most people know, and it is the reason the CDC’s 2022 guideline lists it as having “less respiratory depression” than full agonists.

A ceiling is not a guarantee of safety. Buprenorphine still carries the opioid class boxed warnings, and the ceiling can be overwhelmed when it is combined with alcohol, benzodiazepines, or other sedatives – the same combinations that drive most opioid deaths. Because it grips the receptor so tightly, naloxone can take more effort to reverse it – a point Dahan’s group also studied. The ceiling lowers one of the biggest risks. It does not remove the others.

Two families of products

Part of the confusion is that “buprenorphine” is really two shelves of medicine. The products approved for opioid use disorder – Suboxone and its generics, Sublocade, and others – are films, tablets, or injections, often combined with naloxone, built to hold a person steady and stop withdrawal and craving. The products approved for pain are different: Butrans is a seven-day skin patch, and Belbuca is a film that dissolves against the inside of the cheek. Both carry the same FDA indication, word for word: “severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options.” The amounts differ a great deal between the two shelves, which is one reason the choice of product belongs with your prescriber.

Clinicians also sometimes use the opioid-use-disorder products for pain when the pain products do not reach high enough, and the CDC guideline describes exactly that situation. It is a legitimate use, not a statement about who you are.

What the 2025 trial actually showed

The most rigorous test of buprenorphine as a way off high-dose opioids was published in JAMA Internal Medicine in 2025 by Becker, Krebs, and the VOICE study group. It enrolled 207 veterans with moderate to severe chronic pain who had been on a high-dose, full-agonist opioid – at least 70 morphine milligram equivalents a day – for at least three months. Half were randomly assigned to be offered the option of switching to buprenorphine; half were not offered it. The main outcome was the Brief Pain Inventory total score a year later, with the opioid dose as the main secondary outcome.

Here is what happened. In the group offered the switch, the average pain score fell from 6.8 to 6.1 on a 0–10 scale, and the average full-agonist opioid dose fell from about 157 to 94 morphine milligram equivalents a day. Those are real changes: pain did not get worse as the opioid dose dropped by roughly 40 percent. But the group that was not offered buprenorphine did almost exactly the same – pain from 6.8 to 6.3, dose from 165 to 107. The difference between the two groups was essentially zero on both measures. And only 27 of the 104 people offered the switch, about one in four, actually made it.

How to read that result

It would be easy to spin this trial either way, and the honest reading is in the middle. It does not show that buprenorphine is a better pain reliever than the opioids people were already taking. It does show something patients on high-dose opioids are often told is impossible: that a large reduction in full-agonist opioids, done gradually with support, was accompanied by a small improvement in pain, not a collapse. That finding held whether or not buprenorphine was on offer, which suggests the collaborative care and the slow, supported dose reduction were doing much of the work.

The trial also had limits worth naming. It was almost entirely male, it ran in one health system, and because so few people switched, it cannot tell us much about what happens to those who do. The strongest statement the evidence supports today is this: for someone on high-dose opioids whose pain is no better, buprenorphine is a reasonable option that a careful trial found neither harmful nor magical.

Who clinicians consider it for

The CDC guideline is specific. It suggests that patients for whom the risks of continued high-dose opioids outweigh the benefits, who have not been able to taper, and who do not have opioid use disorder might benefit from a transition to buprenorphine. Physicians also raise it when a person on a full-agonist opioid has sleep-disordered breathing, takes other sedating medications, or seems caught in the trap where rising doses bring rising pain – the opioid-induced hyperalgesia described on our opioid stewardship page. It is not usually a first opioid, and it does not replace the non-opioid treatments that remain the foundation of chronic pain care.

What switching involves, in general terms

Because buprenorphine grips the receptor so tightly, it can push a full agonist off – and if the full agonist is still present in quantity, that sudden displacement can trigger precipitated withdrawal: a fast, miserable onset of sweating, aching, cramping, and anxiety. Avoiding that is the whole craft of the switch. Clinicians use one of two broad approaches: a planned gap in which the previous opioid wears off and mild withdrawal begins before buprenorphine starts, or a slower overlap in which very small amounts of buprenorphine are introduced while the previous opioid is reduced. Which approach, how long it takes, and what the numbers are depend entirely on which opioid you take, how much, and your health – which is why this page describes the shape of the process and does not give schedules.

What you can expect is close follow-up – in the trial, people who switched had structured check-ins to adjust the amount and manage side effects. Common side effects are familiar opioid ones – nausea, constipation, drowsiness, headache – plus, with the patch, skin irritation at the site, and the label warns against heating pads or hot baths over a patch because heat speeds absorption. Buprenorphine can also affect heart rhythm at higher amounts, which is something your prescriber weighs against your other medications.

Two safety lines do not change when the medication does. Any opioid taken with alcohol, benzodiazepines, or sleep medicines can stop breathing, and the ceiling does not protect against that combination. And if someone taking any opioid cannot be woken, is breathing slowly or in gasps, or has blue lips, that is an emergency: call 911 and give naloxone if it is on hand, then give it again if there is no response. If a transition is turning into a struggle, or if you are worried about your own use of opioids or anyone else’s, the SAMHSA helpline, 1-800-662-4357, is free, confidential, and answers around the clock.

How it fits with your other options

Buprenorphine sits late in the treatment ladder, in the same rung as every other long-term opioid for chronic non-cancer pain. The classes that come before it – and that keep working alongside it – are mapped on our medications for pain page, and the different question of opioids after surgery or injury is on opioids for acute pain. If you are already on a high-dose opioid and your pain is no better, the trial’s most useful message may be the simplest one: you are not imagining that the medicine has stopped helping, and there is more than one careful way forward. Bring the question to your physician or pharmacist. This page describes; it does not prescribe.